Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy

Inclusion Criteria: * Males or females aged 18 years to 80 years at the time of screening. * Ability to understand and willingness to sign a written informed consent document. * Subjects must have advanced histologically or cytologically confirmed solid tumor or relapsed or refractory Non-Hodgkin lymphoma. * Adequate bone marrow, liver, and renal functions. * Men and women of childbearing potential must agree to take highly effective contraceptive methods. * Women of reproductive potential must have negative serum beta human chorionic gonadotropin (β -HCG) pregnancy test within 7 days of the first dose. Exclusion Criteria: * Receipt of systemic anticancer therapy including investigational agents or devices within 5 half-lives of the first dose of study treatment. * Known active CNS metastasis. * Has received a live-virus vaccine within 28 days. * History of clinically significant sensitivity or allergy to monoclonal antibodies and their excipients or known allergies to antibodies produced from Chinese hamster ovary cells. * Abnormality of QT interval or syndrome. * Patients with history of Grade ≥ 3 immune-related AEs (irAEs) or irAE. * Patients who receive concurrent or prior use of an immunosuppressive agent within 4 weeks of the first dose of study drug. * Previous exposure to anti-CD137 (eg, utomilumab, urelumab) antibodies. . * Active or chronic autoimmune disease that has required systemic treatment in the past 3 years or who are receiving systemic therapy for an aut…